IVF and Fertility in Indian Group Health: What the Standard Exclusion Says and What Employers Buy Instead

On 19 August 2026, CNBC TV18 published an explainer on what health insurance may and may not cover for IVF treatment, and Whalesbook reported that India's IVF market faces a persistent coverage gap as high treatment costs continue. Two different audiences, one arithmetic problem: the cost of assisted reproduction in India keeps rising, and the insurance products most Indians hold, retail health policies and employer group mediclaim, mostly do not pay for it.

The cost shape is what makes the gap painful. A single IVF cycle in a metro clinic commonly runs into several lakh rupees once medication, monitoring, laboratory charges and embryo freezing are added to the base procedure fee, and a meaningful share of patients need more than one cycle before a successful outcome. Unlike a hospitalisation, the spend arrives as a planned, repeatable outpatient-heavy episode, which is close to the opposite of what an indemnity health policy is designed to fund.

For benefits teams the question has stopped being academic. Fertility support now shows up in benefits surveys and candidate conversations at GCCs and technology employers, whose workforces skew toward exactly the age band where fertility treatment decisions are made. The broker sitting between that demand and the standard group wording is being asked to price something the base product was drafted to exclude.

The exclusion is not an insurer quirk. It is standardised. The IRDAI Guidelines on Standardization of Exclusions in Health Insurance Contracts, 2019 define a uniform exclusion for sterility and infertility, listed in wordings as Code Excl 17. The standard text excludes expenses related to sterility and infertility, including contraception and sterilisation, assisted reproduction services such as artificial insemination and advanced reproductive technologies including IVF, ZIFT, GIFT and ICSI, gestational surrogacy, and reversal of sterilisation.

Group mediclaim wordings in India generally carry this exclusion verbatim or in near-identical form. That drafting has three practical consequences worth reading closely.

• The exclusion attaches to the purpose of the expense, not the venue. An IVF-related procedure does not become payable because it involved daycare admission or because a related hospitalisation occurred.
• "Expenses related to" sweeps in the surrounding spend: hormonal stimulation medication, cycle monitoring, and laboratory charges typically fall with the procedure itself.
• Treatment of an underlying medical condition is a separate question from treatment for conception. Surgery for a gynaecological condition that also impairs fertility is adjudicated on its own merits under the base policy; the same patient's IVF cycle is not. Claims disputes in this area usually turn on which side of that line an expense sits, which makes the policy wording and the treating doctor's documentation decisive.

The demand side has shifted faster than the product. Business Today reported on 18 August 2026 that India Inc is investing in personalised welfare programmes for employees, benefits tuned to life stage and individual circumstance rather than a uniform grade-wise entitlement. Fertility support is one of the clearest examples of that logic: it is irrelevant to most of the workforce in any given year and intensely valuable to the employees it touches, typically mid-career professionals an employer least wants to lose.

The same week, The Times of India reported on 17 August 2026 that companies are tightening employee perks under cost and productivity pressure. The two stories are not in conflict. Broad, low-signal perks are being trimmed while spend concentrates on benefits with measurable retention value. A fertility benefit is a targeted, high-salience commitment to a defined employee segment, which is exactly the shape of spend that survives a perks review.

GCCs feel this first. Their benefits benchmarks are set partly by global parent programmes, where fertility benefits are established practice among large United States employers, and their talent competition is with other GCCs making the same comparison. When a candidate's current employer offers fertility support and the offer on the table does not, the gap is concrete and easy to price. That is how a standard exclusion in a group wording becomes a line item in an attrition conversation.

Group health in India is a negotiated product. The base wording carries the standard exclusion, but insurers will modify group terms by endorsement for a priced premium, and infertility carve-backs are now a recurring ask in large-account placements. The carve-backs that appear in practice share a family resemblance.

• A capped sub-limit, not open indemnity. Cover is granted up to a stated amount per family, commonly positioned alongside or inside the maternity benefit, and modest relative to the real cost of treatment. The sub-limit is the insurer's control on a benefit with high election rates once announced.
• Cycle and lifetime caps. Wordings may cap the number of IVF cycles, or state the limit as a per-policy-period or lifetime amount per family, so that the benefit cannot be drawn indefinitely across renewals.
• Scope carve-outs within the carve-back. Diagnostic work-up may be covered while treatment is not, or IUI covered while IVF is not. Donor gametes and gestational surrogacy usually remain excluded even where IVF is covered.
• Eligibility gates. Waiting periods, a minimum period of infertility diagnosis, or restriction to employee and spouse rather than all dependants.
• Registered facilities only. Following the Assisted Reproductive Technology (Regulation) Act, 2021, which requires ART clinics and banks to be registered, carve-backs typically pay only for treatment at registered clinics.

Each of these is an endorsement negotiated at placement or mid-term, priced against the group's demographics, and administered through the same TPA and CD account machinery as any other group endorsement. The premium load is real: the insurer is pricing a benefit with near-certain utilisation by those who elect it, in a market where group health premiums are already hardening under medical inflation. A fertility carve-back also lands in the group's claims experience, so a well-used benefit feeds directly into next year's renewal negotiation.

The other route does not go through the insurer at all. The employer commits a defined amount per eligible employee, a fertility wallet, and reimburses treatment expenses against it, usually through a benefits administration platform or the TPA's flex-benefits module rather than the insurance policy. The 19 August 2026 PR Newswire announcement that Healthcare Management Administrators is partnering with Carrot to deliver fertility and family care benefits to employer groups in the United States illustrates the model: a third-party administrator plugs a specialist fertility-benefits platform into employer plans, with the employer funding the benefit and the platform handling clinic networks, case management and claims logic.

The Indian translation of that model is already visible in how domestic benefits platforms and TPAs structure flex wallets. The design variables are the same everywhere:

1. The cap. A lifetime amount per employee or per family, set by budget rather than actuarial pricing. The employer knows its maximum outflow on day one.
2. The eligible-expense list. The employer decides what the wallet pays for: diagnostics, IUI, IVF cycles, medication, cryopreservation, adoption or surrogacy support. Nothing is constrained by Code Excl 17 because no insurance contract is involved.
3. The clinic network. Restricting reimbursement to ART-registered clinics, or to a negotiated panel, controls both quality and price per cycle.
4. Case management. The strongest versions of the model add clinical guidance before and during treatment, which affects outcomes and total spend more than the funding mechanism does.

The wallet's weakness is the mirror of its strength. Because it is not insurance, there is no risk transfer: a year with unusually high uptake lands entirely on the employer's P&L. For a large employer the cap per employee bounds this acceptably. For a small one, a handful of simultaneous claimants can consume the entire benefits contingency.

Brokers are increasingly asked to put the two structures side by side. The comparison runs on three axes: cost and risk, tax treatment, and the administrative load each structure creates.

Cost and risk

The insured rider converts an uncertain outflow into a fixed premium, but the premium carries the insurer's loadings and, for employer group policies, 18% GST, for which input tax credit is generally blocked under Section 17(5) of the CGST Act unless the cover is statutorily obligatory. The wallet has no premium, no GST on a policy, and no insurer margin, but retains the utilisation risk. Because fertility treatment is elective and largely predictable in aggregate for a large workforce, the case for paying an insurer to carry it is weaker than for genuinely fortuitous risks; this is the same logic that pushes high-frequency, low-severity benefits like OPD toward funded rather than insured structures. The rider's hidden cost is renewal drag: claims under the carve-back sit in the group's burn and reprice the whole group health programme at renewal, while wallet spend never touches the claims ratio.

Tax treatment

Premium an employer pays on a group health insurance policy for employees is deductible business expenditure and is not taxed as a perquisite in employee hands. A fertility wallet is different: cash reimbursement of private medical treatment is, as a general position, taxable salary or perquisite for the employee, since the older blanket medical-reimbursement exemption no longer exists. The net-of-tax value of a Rs 2 lakh wallet is therefore materially less than its face value for an employee in the top slab, and employers should take specific tax advice on structuring before announcing a figure. This asymmetry is the strongest argument for the insured route where the benefit amounts are similar.

The rider runs on rails that already exist: TPA adjudication, network billing, endorsement and CD-account accounting. The wallet needs a platform, an eligible-expense policy the employer must draft and defend, and a reimbursement workflow that handles sensitive medical information with tighter access control than routine claims, since fertility treatment data is among the most private information an employer-adjacent system will ever hold under the Digital Personal Data Protection Act, 2023. Neither structure is administratively free; the wallet simply moves the work from the insurer to the employer and its platform.

The practical advice depends on employer size and intent.

For large employers and GCCs that want a headline benefit, the structures are complements rather than rivals: a modest insured carve-back inside the group policy for the medical core, plus a capped wallet for everything the insurer will not touch, donor treatment, adoption support, additional cycles beyond the insured limit. The insured layer captures the tax efficiency; the wallet supplies the breadth that makes the programme competitive against global benchmarks.

For mid-market employers, the honest starting point is the wallet, sized to budget, with a panel of ART-registered clinics and a clear eligible-expense list. An insured carve-back priced for a 300-life group frequently costs more in premium and renewal drag than the benefit it delivers.

In either case, the wording and policy questions to settle before launch:

1. Exactly which expenses are in scope: diagnostics, medication, IUI, IVF, ICSI, cryopreservation, donor cycles, surrogacy.
2. The cap architecture: per cycle, per year, per family, lifetime, and what happens to an unused balance on exit.
3. How the carve-back interacts with the maternity benefit and with Code Excl 17 as drafted in the base wording, confirmed in the endorsement text rather than the quote slip.
4. Eligibility: waiting periods, dependant definitions, and whether single employees and same-sex partners are inside the benefit.
5. Data handling: who sees claim details, and how the platform or TPA segregates fertility claims data.

Comparing carve-back endorsements across insurers requires the endorsement wordings themselves, not the premium comparison sheet. Sarvada gives brokers and corporate benefits teams searchable access to group health wordings and endorsement intelligence, so exclusion carve-backs, sub-limits and maternity interactions can be compared line by line before a placement is signed. Teams weighing a fertility rider against a funded wallet can Request Access to run that comparison.